AMR: ENABLE selects Mutabilis candidate
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
NSCLC: Bemcentinib + anti-PD1 triple PFS
/in News/by Thomas GabrielczykBergen Bio ASAs Axl kinase blocker bemcentinib in combination with MSDs pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer […]
Transposase makes CAR-T production cheaper
/in News/by Thomas GabrielczykGerman researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies.
Test detects breast cancer in earliest stage
/in News/by Thomas GabrielczykBreast cancer might be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced […]
Sherlock Bioscience and Mologic enter partnership
/in News/by Thomas GabrielczykSynbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource […]
Protein protects against liver fibrosis
/in News/by Thomas GabrielczykGerman researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver.
bit bio restarts with new management
/in News/by Thomas GabrielczykCell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
Researchers identify viral inflammation switch
/in News/by Thomas GabrielczykA team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
Rotavirus vaccines kill cancer cells
/in News/by Thomas GabrielczykResearchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Polyphor presents AMR breaker
/in News/by Thomas GabrielczykSwiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.